Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
Aquestive Therapeutics shares surged 137.29% (YoY) after FDA approval of rival company ARS Pharmaceutical's "epinephrine nasal spray" Neffy. Market optimism surrounds AQST's robust R&D pipeline, with analysts giving outperform rating and price target increase to $15. AQST recorded significant revenue growth in Q2 2024, with a cash balance of $89.87 million and sufficient funds until the end of 2026.
Aquestive Therapeutics Inc. (AQST) Q2 2024 Earnings Call Transcript
Aquestive Therapeutics Inc. (NASDAQ:AQST ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Bennett Watson - ICR Westwicke Investor Relations Dan Barber - Chief Executive Officer Ernie Toth - Chief Financial Officer Carl Kraus - Chief Medical Officer Stephen Wargacki - Chief Science Officer Sherry Korczynski - Senior Vice President of Sales and Marketing Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Sandler François Brisebois - Oppenheimer Raghuram Selvaraju - H.C. Wainwright Thomas Flaten - Lake Street Securities Jason Butler - Citizens JMP Gary Nachman - Raymond James James Molloy - Alliance Global Partners Operator Good morning, and welcome to the Aquestive Therapeutics Second Quarter 2024 Conference Call.
Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.10 per share a year ago.
New Strong Sell Stocks for July 11th
AQST, CENTA and RAMP have been added to the Zacks Rank #5 (Strong Sell) List on July 11, 2024.
